65331
document
[ The effects of tirofiban on acute non-ST segment elevation myocardial infarction patients not receiving early reperfusion intervention ] . OBJECTIVE To study the efficacy and safety of tirofiban in patients with acute non-ST- segment elevation myocardial infarction ( NSTEMI ) without early reperfusion intervention . METHODS A total of 151 NSTEMI patients without early reperfusion intervention were enrolled in the study and randomized to the tirofiban group ( n = 76 ) and the control group ( n = 75 ) . Coronary angiography was performed at day 3 and day 7 , while percutaneous coronary intervention ( PCI ) was performed when necessary . Parameters including thrombolysis in myocardial infarction ( TIMI ) flow , bleeding complications and clinic events within 30 days were compared between the two groups . RESULTS Before PCI , no increase in the percentage of patient with TIMI flow better than TIMI-2 was observed by the treatment of tirofiban ( 69.3 % vs 78.9 % , P = 0.10 ) . While after PCI , significant increase in the percentage of patient with TIMI flow better than TIMI-2 was manifested in the tirofiban group ( 96.0 % vs 100.0 % , P = 0.04 ) . Tirofiban treatment also significantly decreased the rate of poor myocardial perfusion after PCI ( 19.7 % vs 34.7 % , P = 0.04 ) . There were 0 and 4 major adverse cardiovascular events ( MACE ) within 30 days observed in the tirofiban group and the control group ( 0.0 % vs 5.3 % , P = 0.05 ) . No difference between the two groups was found in the bleeding complications within 30 days including the mild hemorrhage ( 5 vs 4 cases , P = 0.75 ) , severe hemorrhage ( 2 vs 1 cases , P = 0.56 ) or severe thrombocytopenia ( 2 vs 0 cases , P = 0.49 ) . CONCLUSIONS Tirofiban treatment does not increase the bleeding complications in NSTEMI patients without early PCI . Tirofiban can improve the TIMI flow and the myocardial perfusion after PCI with less MACE within 30 days .
65332
Intervention_Pharmacological
tirofiban
65333
Intervention_Pharmacological
tirofiban
65334
Intervention_Pharmacological
tirofiban
65335
Intervention_Control
control group
65336
Intervention_Surgical
Coronary angiography
65337
Intervention_Surgical
intervention
65338
Intervention_Pharmacological
tirofiban
65339
Intervention_Pharmacological
tirofiban
65340
Intervention_Pharmacological
tirofiban
65341
Outcome_Physical
myocardial infarction
65342
Outcome_Other
efficacy and safety
65343
Outcome_Physical
thrombolysis in myocardial infarction ( TIMI ) flow
65344
Outcome_Adverse-effects
bleeding complications
65345
Outcome_Physical
percentage of patient with TIMI flow
65346
Outcome_Physical
percentage of patient with TIMI flow
65347
Outcome_Physical
rate of poor myocardial perfusion
65348
Outcome_Adverse-effects
major adverse cardiovascular events ( MACE )
65349
Outcome_Adverse-effects
bleeding complications
65350
Outcome_Adverse-effects
mild hemorrhage
65351
Outcome_Adverse-effects
severe hemorrhage
65352
Outcome_Adverse-effects
severe thrombocytopenia
65353
Outcome_Adverse-effects
bleeding complications
65354
Participant_Condition
myocardial infarction
65355
Participant_Condition
acute non-ST- segment elevation myocardial infarction ( NSTEMI )
65356
Participant_Sample-size
151
65357
Participant_Condition
NSTEMI
65358
Participant_Condition
NSTEMI